secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001104659-24-068948
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune reports positive IGNYTE primary analysis: ORR 33.6% in anti-PD1 failed melanoma; BLA submission planned 2H2024
--------------------------------------------------------------------------------

- Primary analysis shows ORR 33.6% (modified RECIST 1.1) and 32.9% (RECIST 1.1) by independent central review; all responses >6 months, median DOR >35 months.
- BLA submission intended for 2H2024; confirmatory IGNYTE-3 trial first patient expected Q3 2024.
- Safety: predominantly Grade 1-2 constitutional events; no Grade 5 events; low incidence of Grade 3-4 incidents.
- Data improves on investigator-assessed results presented at ASCO 2024; FDA-requested RECIST 1.1 analysis included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924068948/0001104659-24-068948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924068948/tm2416613d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-068948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer